Rovi to help Spanish government develop flu vaccines
This article was originally published in Scrip
Executive Summary
The Spanish company Rovi is to license Novavax's recombinant virus-like particle vaccine technology as part of a project to help Spain meet its own seasonal and pandemic flu vaccine requirements.